Related Experiment Videos
Mutations in the ras protooncogenes are rare events in renal cell cancer
C F Rochlitz1, S Peter, G Willroth
1Abt. Hämatologie/Onkologie, Klinikums Charlottenburg, Freien Universität Berlin, F.R.G.
Abstract:
Mutations in codon 12, 13 or 61 of one of the three ras genes, Ha-ras, Ki-ras, and N-ras, convert these genes into active oncogenes. To determine the role mutated ras genes play in the carcinogenesis of renal cell carcinoma, we analysed tumour DNA and unaffected renal tissue derived from 55 patients. The polymerase chain reaction technique was used to amplify DNA fragments containing Ki-, Ha-, and N-ras codons 12, 13, and 61. The amplified fragments were then probed on slot-blots with labeled mutation-specific oligomers. A single Ki-ras mutation (codon 12, gly- greater than val) was detected in a patient with a pT2N2M1 tumour. We concluded that ras oncogene mutations do not play an important role in the initiation of renal cell carcinoma.
Insights
Ras oncogene mutations are uncommon in renal cell carcinoma initiation. A study of 55 patients found only one Ki-ras mutation, suggesting these genetic alterations are not a primary driver of kidney cancer development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ras genes (Ha-ras, Ki-ras, N-ras) act as oncogenes when mutated at specific codons (12, 13, or 61).
- Understanding the role of ras mutations in renal cell carcinoma (RCC) is crucial for cancer research.
Purpose of the Study:
- To investigate the involvement of mutated ras genes in the carcinogenesis of renal cell carcinoma.
- To analyze ras gene mutations in tumor DNA from RCC patients.
Main Methods:
- DNA was extracted from tumor and unaffected renal tissues of 55 patients.
- Polymerase chain reaction (PCR) amplified DNA fragments containing ras codons 12, 13, and 61.
- Mutation-specific oligonucleotide probes were used for slot-blot hybridization to detect mutations.
Main Results:
- A single mutation was detected: a Ki-ras mutation at codon 12 (glycine to valine) in one patient with advanced RCC (pT2N2M1).
- No mutations were found in Ha-ras or N-ras genes across the analyzed samples.
- The overall frequency of ras oncogene mutations in this RCC cohort was very low.
Conclusions:
- Ras oncogene mutations do not appear to play a significant role in the initiation of renal cell carcinoma.
- Further research may explore other genetic pathways involved in RCC development.